Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25295887 | 0.91 | LTA4H (0.45) | LTA4HTAAR1LMNAFFAR1 | |
| Hydrochloric Acid SCHEMBL25260760 | 0.88 | LTA4H (0.45) | LTA4HTAAR1LMNAFFAR1 | |
| SCHEMBL4838190 | 0.88 | LTA4H (0.53) | LTA4HLMNAMAOB | |
| Hydrochloric Acid SCHEMBL25376075 | 0.86 | LTA4H (0.52) | LTA4HLMNAMAOB | |
| SCHEMBL27545059 | 0.86 | ADRB2 (0.54) | LTA4HLMNAL3MBTL1ADRB2ADRB1 | |
| SCHEMBL14162906 | 0.86 | ALDH1A1 (0.60) | LTA4HLMNAL3MBTL1ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL25298359 | 0.85 | ITGB3 (0.43) | LTA4HTAAR1LMNAFFAR1MAOB | |
| SCHEMBL188550 | 0.84 | MAPT (0.50) | LTA4HLMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL10869249 | 0.84 | TAAR1 (0.47) | TAAR1LMNAMAOB | |
| SCHEMBL28588481 | 0.83 | LMNA (0.56) | LTA4HLMNAL3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205291-B | Triazolo ring compound, preparation method, intermediate and application thereof | 上海科技大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-111205291-A | Triazolo ring compound, preparation method, intermediate and application thereof | 上海科技大学 | 2020-05-29 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | LTA4H 1742/4885TAAR1 509/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.